PLAINSBORO, N.J., Oct. 2, 2023 /PRNewswire/ — Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved Rivfloza (nedosiran) injection 80 mg, 128 mg, or 160 mg, a once-monthly subcutaneous ribonucleic acid…Original Article
You may also like
Apellis Announces U.S. FDA Approval of the Empaveli...
FDA Approves Technegas (Technetium Tc 99-m Labeled...
FDA Approves Tofidence (tocilizumab-bavi), a...
FDA Approves Exxua (gepirone) for the Treatment of...
FDA Approves Pombiliti (cipaglucosidase alfa-atga) +...
U.S. FDA Approves Subcutaneous Administration of...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.